<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>麦肯锡见解与出版物</title><description>麦肯锡见解与出版物 RSS 源</description><link/>https://www.mckinsey.com/<image/><url> http://www.mckinsey.com/assets/dotcom/newsletters/images/mckinsey_logo_sm.jpg</url><title>麦肯锡见解与出版物</title><link/>https://www.mckinsey.com/<pubDate> Tue, 01 Sep 2015 08:44:43 GMT</pubDate><language> zh</language><copyright>版权所有 (c) 麦肯锡公司。版权所有。经许可转载。</copyright><generator> Sitecore CMS：http://www.sitecore.net。 Sitecore RSS 模块：McKinsey.RSS，版本=1.3.2.8895，文化=中性，PublicKeyToken=null</generator><item><title>业务建设的隐藏陷阱：生命科学首席执行官指南</title><description>制药、生物技术和医疗技术领域的首席执行官越来越多地建立以患者为中心的业务，但目前进展缓慢。避免五个常见障碍可以帮助领导者建立成功的企业。</description><link/> https://www.mckinsey.com/industries/life-sciences/our-insights/the-hidden-traps-of-business-building-a-guide-for-life-science-ceos<guid> 1aff359f-a93f-4a6d-9206-fe4ccdc022ff</guid><pubDate> Fri, 10 Jan 2025</pubDate><category>生命科学见解</category><category>卫生保健</category><category>人工智能</category><category>战略</category></item><item><title>绘制通往患者的路径</title><description>在整个制药研发管道中仔细制定资产战略对于抓住创新机会变得越来越重要。</description><link/> https://www.mckinsey.com/industries/life-sciences/our-insights/charting-the-path-to-患者<guid>44f75867-277d-4d08-b356-0206eca27c48</guid><pubDate> Thu, 09 Jan 2025</pubDate><category>生命科学见解</category><category>药品</category><category>北美洲和中美洲</category><category>创新</category></item><item><title>外部创新：生物制药交易以提高研发效率</title><description>过去十年中表现最好的制药公司依赖于一系列关键的交易行为来推动外部创新生产力的提高。</description><link/> https://www.mckinsey.com/industries/life-sciences/our-insights/external-innovation-biopharma-dealmaking-to-boost-r-and-d-productivity<guid> dfc49d92-5bb6-413d-8c96-02bc9f1a1ea1</guid><pubDate> Thu, 09 Jan 2025</pubDate><category>生命科学见解</category><category>生物技术</category></item><item><title>建立药品研发与供应商合作伙伴关系的共同愿景</title><description>制药研发领导者及其供应商将透明度视为实现更有效合作和成本效率的关键。</description><link/> https://www.mckinsey.com/industries/life-sciences/our-insights/building-a-shared-vision-for-pharma-r-and-d-supplier-partnerships<guid> 404964c8-764f-4a91-9af0-497df7af66e5</guid><pubDate> Thu, 09 Jan 2025</pubDate><category>生命科学见解</category><category>药品</category></item><item><title>利用人工智能解锁临床开发中的最佳运营绩效</title><description>三个灯塔用例作为人工智能提高临床试验速度、效率和质量潜力的蓝图。</description><link/> https://www.mckinsey.com/industries/life-sciences/our-insights/unlocking-peak-operational-performance-in-clinical-development-with-artificial-intelligence<guid> a3580b46-3817-43d4-b961-5c9135985d04</guid><pubDate> Thu, 09 Jan 2025</pubDate><category>生命科学见解</category><category>药品</category><category>人工智能</category></item><item><title>将人置于生命科学研发人才模型的中心</title><description>科学技术的快速进步正在挑战制药和生物技术公司的人才方法。他们今天需要哪些研发技能，以及如何维持这支劳动力队伍？</description><link/> https://www.mckinsey.com/industries/life-sciences/our-insights/putting-people-at-the-center-of-the-r-and-d-talent-model-in-life-sciences<guid> 60bd803f-f49f-429c-b263-7b20396b3f01</guid><pubDate> Thu, 09 Jan 2025</pubDate><category>生命科学见解</category><category>生物技术</category><category>北美洲和中美洲</category><category>天赋</category></item><item><title>生物制药研究和早期开发的卓越运营</title><description>领先的公司正在改进研究和早期开发，以遏制漫长的药物开发时间和不断上升的成本。</description><link/> https://www.mckinsey.com/industries/life-sciences/our-insights/operational-excellence-in-biopharma-research-and-early-development<guid> 78ac1b15-a469-40ee-a807-638c1140425b</guid><pubDate> Thu, 09 Jan 2025</pubDate><category>生命科学见解</category><category>生物技术</category></item><item><title>利用下一代技术堆栈提高生物制药研发绩效</title><description>精心设计的现代技术堆栈可以释放人工智能、自动化和数据的潜力及其对研发生产力的承诺优势。</description><link/> https://www.mckinsey.com/industries/life-sciences/our-insights/boosting-biopharma-r-and-d-performance-with-a-next- Generation-technology-stack<guid> 48823d46-d4d2-46c0-803f-c6beaa38f83d</guid><pubDate> Thu, 09 Jan 2025</pubDate><category>生命科学见解</category><category>药品</category><category>数字的</category><category>分析</category></item><item><title>生物制药领导者如何优化其投资组合策略</title><description>领先的生物制药公司管理其临床管道以优化风险和回报。方法如下。</description><link/> https://www.mckinsey.com/industries/life-sciences/our-insights/how-biopharmaceutical-leaders-optimize-their-portfolio-strategies<guid> 2ce8b751-c946-4647-99ff-ffc784b74458</guid><pubDate> Thu, 09 Jan 2025</pubDate><category>生命科学见解</category><category>药品</category><category>北美洲和中美洲</category><category>创新</category></item><item><title>量身定制的经济赋权：企业如何让更多人受益</title><description>联系、背景和能力可以指导企业有效地创造赋权影响。</description><link/> https://www.mckinsey.com/mgi/our-research/economic-empowerment-made-to-measure-how-companies-can-benefit-more-people<guid> d5b78224-31e7-4194-bf9b-23c3ad02b9d4</guid><pubDate> Wed, 08 Jan 2025</pubDate><category>研究</category><category>华大智造研究</category></item><item><title>艾伯维 (AbbVie) 基因组学研究负责人探讨人工智能的变革力量</title><description>艾伯维 (AbbVie) 基因组学研究副总裁兼数据集成主管 Howard Jacob 分享了他对个性化数据、人工智能和机器学习在预防和治疗疾病方面的潜力的看法。</description><link/> https://www.mckinsey.com/industries/life-sciences/our-insights/abbvies-head-of-genomics-research-on-the-transformative-power-of-ai<guid> be572df9-9d0e-4f51-b1e0-36a94e770c7e</guid><pubDate> Wed, 08 Jan 2025</pubDate><category>生命科学见解</category><category>药品</category><category>美国</category><category>人工智能</category></item></channel></rss>